摘要
The aim of this study is to assess the variability of 2-deoxy-2-[F-18]fluoro--glucose ([F-18]-FDG) and 3%26apos;-deoxy-3%26apos;-[F-18]-fluorothymidine ([F-18]-FLT) uptake in pre-clinical tumor models and examine the relationship between imaging data and related histological biomarkers. %26lt;br%26gt;[F-18]-FDG and [F-18]-FLT studies were carried out in nine human tumor xenograft models in mice. A selection of the models underwent histological analysis for endpoints relevant to radiotracer uptake. Comparisons were made between uptake, imaging, and histopathology data using quantitative and semi-quantitative analysis. %26lt;br%26gt;data revealed that [1-C-14]-2-deoxy--glucose ([C-14]-2DG) uptake in the tumor cell lines was variable. , [F-18]-FDG and [F-18]-FLT uptake was highly variable across tumor types and uptake of one tracer was not predictive for the other. [C-14]-2DG uptake did not predict for [F-18]-FDG uptake . [F-18]-FDG SUV was inversely proportional to Ki67 and necrosis levels and positively correlated with HKI. [F-18]-FLT uptake positively correlated with Ki67 and TK1. %26lt;br%26gt;When evaluating imaging biomarkers in response to therapy, the choice of tumor model should take into account baseline radiotracer uptake, which can vary significantly between models.
- 出版日期2012-6